Value of GATA3 immunostaining in tumor diagnosis: A review

Advances in Anatomic Pathology

Volumn 20, Issue 5, 2013, Pages 352-360

  Ordóñez, Nelson G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

breast carcinoma; GATA3; immunohistochemistry; parathyroid tumor; urothelial carcinoma

Indexed keywords

THROMBOMODULIN; TRANSCRIPTION FACTOR GATA 3; TUMOR MARKER;

ARTICLE; BREAST CARCINOMA; CANCER DIAGNOSIS; DIFFERENTIAL DIAGNOSIS; EPITHELIUM TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; PARATHYROID CARCINOMA; PRIORITY JOURNAL; SALIVARY GLAND TUMOR; SQUAMOUS CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA; TUMOR DIAGNOSIS; UROGENITAL TRACT TUMOR;

ANTIBODIES; BIOPSY; BREAST NEOPLASMS; CARCINOMA; DIAGNOSIS, DIFFERENTIAL; FEMALE; GATA3 TRANSCRIPTION FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASMS; PARATHYROID NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84883333911     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e3182a28a68     Document Type: Article

References (103)

1. Patient RK, McGhee JD. The GATA family (vertebrates and invertebrates). Curr Opin Genet Dev. 2002;12:416-422.
2. Cantor AB, Orkin SH. Transcriptional regulation of erythropoiesis: An affair involving multiple partners. Oncogene. 2002;21:3368-3376.
3. Grogan JL, Locksley RM. T helper cell differentiation: on again, off again. Curr Opin Immunol. 2002;14:366-372.
4. Ohneda K, Yamamoto M. Roles of hematopoietic transcription factors GATA-1 and GATA-2 in the development of red blood cell lineage. Acta Haematol. 2002;108:237-245.
5. Morrisey EE, Ip HS, Lu MM, et al. GATA-6: A zinc finger transcription factor that is expressed in multiple cell lineages derived from lateral mesoderm. Dev Biol. 1996;177:309-322.
6. Molkentin JD. The zinc finger-containing transcription factors GATA-4, -5, and -6. Ubiquitously expressed regulators of tissue-specific gene expression. J Biol Chem. 2000; 275:38949-38952.
7. Molkentin JD, Tymitz KM, Richardson JA, et al. Abnormalities of the genitourinary tract in female mice lacking GATA5. Mol Cell Biol. 2000;20:5256-5260.
8. Chou J, Provot S, Werb Z. GATA3 in development and cancer differentiation: Cells GATA have it! J Cell Physiol. 2010;222:42-49.
9. Pandolfi PP, Roth ME, Karis A, et al. Targeted disruption of the GATA3 gene causes severe abnormalities in the nervous system and in fetal liver haematopoiesis. Nat Genet. 1995; 11:40-44.
10. LaVoie HA. The role of GATA in mammalian reproduction. Exp Biol Med. 2003;228:1282-1290.
11. Ho IC, Vorhees P, Marin N, et al. Human GATA-3: A lineage-restricted transcription factor that regulates the expression of the T cell receptor alpha gene. EMBO J. 1991; 10:1187-1192.
12. Ko LJ, YamamotoM, LeonardMW, et al. Murine and human T-lymphocyte GATA-3 factors mediate transcription through a cis-regulatory element within the human T-cell receptor delta gene enhancer.Mol Cell Biol. 1991;11:2778-2784.
13. Ting CN, Olson MC, Barton KP, et alTranscription factor GATA-3 is required for development of the T-cell lineage. Nature. 1996;384:474-478.
14. Ho IC, Tai TS, Pai SY. GATA3 and the T-cell lineage: Essential functions before and after T-helper-2-cell differentiation. Nat Rev Immunol. 2009;9:125-135.
15. Hosoya T, Maillard I, Engel JD. From the cradle to the grave: Activities of GATA-3 throughout T-cell development and differentiation. Immunol Rev. 2010;238:110-125.
16. Kouros-Mehr H, Slorach EM, Sternlicht MD, et al. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell. 2006;127:1041-1055.
17. Asselin-Labat ML, Sutherland KD, Barker H, et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol. 2007;9:201-209.
18. Kouros-Mehr H, Kim JW, Bechis SK, et al. GATA-3 and the regulation of the mammary luminal cell fate. Curr Opin Cell Biol. 2008;20:164-170.
19. Grigorieva IV, Mirczuk S, Gaynor KU, et al. Gata3-deficient mice develop parathyroid abnormalities due to dysregulation of the parathyroid-specific transcription factor Gcm2. J Clin Invest. 2010;120:2144-2155.
20. Tong Q, Dalgin G, Xu H, et al. Function of GATA transcription factors in preadipocyte-adipocyte transition. Science. 2000;290:134-138.
21. Grote D, Souabni A, Busslinger M, et al. Pax 2/8-regulated Gata 3 expression is necessary for morphogenesis and guidance of the nephric duct in the developing kidney. Development. 2006;133:53-61.
22. Lim KC, Lakshmanan G, Crawford SE, et al. Gata3 loss leads to embryonic lethality due to noradrenaline deficiency of the sympathetic nervous system. Nat Genet. 2000;25:209-212.
23. Tsarovina K, Pattyn A, Stubbusch J, et al. Essential role of Gata transcription factors in sympathetic neuron development. Development. 2004;131:4775-4786.
24. Moriguchi T, Takako N, Hamada M, et al. Gata3 participates in a complex transcriptional feedback network to regulate sympathoadrenal differentiation. Development. 2006; 133:3871-3881.
25. Maeda A, Moriguchi T, Hamada M, et al. Transcription factor GATA-3 is essential for lens development. Dev Dyn. 2009;238:2280-2291.
26. Kaufman CK, Zhou P, Pasolli HA, et al. GATA-3: An unexpected regulator of cell lineage determination in skin. Genes Dev. 2003;17:2108-2122.
27. Kurek D, Garinis GA, van Doorninck JH, et al. Transcriptome and phenotypic analysis reveals Gata3-dependent signalling pathways in murine hair follicles. Development. 2007;134:261-272.
28. Labastie MC, Bories D, Chabret C, et al. Structure and expression of the human GATA3 gene. Genomics. 1994;21: 1-6.
29. Yang Z, Gu L, Romeo PH, et al. Human GATA-3 transactivation, DNA-binding, and nuclear localization activities are organized into distinct structural domains. Mol Cell Biol. 1994;14:2201-2212.
30. Nesbit MA, Bowl MR, Harding B, et al. Characterization of GATA3 mutations in the hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome. J Biol Chem. 2004;279: 22624-22634.
31. Bilous RW, Murty G, Parkinson DB, et al. Brief report: Autosomal dominant familial hypoparathyroidism, sensorineural deafness, and renal dysplasia. N Engl J Med. 1992;327: 1069-1074.
32. Hasegawa T, Hasegawa Y, Aso T, et al. HDR syndrome (hypoparathyroidism, sensorineural deafness, renal dysplasia) associated with del(10)(p13). Am J Med Genet. 1997;73: 416-418.
33. Van Esch H, Groenen P, Nesbit MA, et al. GATA3 haploinsufficiency causes human HDR syndrome. Nature. 2000; 406:419-422.
34. Oosterwegel M, Timmerman J, Leiden J, et al. Expression of GATA-3 during lymphocyte differentiation and mouse embryogenesis. Dev Immunol. 1992;3:1-11.
35. George KM, Leonard MW, Roth ME, et al. Embryonic expression and cloning of the murine GATA-3 gene. Development. 1994;120:2673-2686.
36. Labastie MC, Catala M, Gregoire JM, et al. The GATA-3 gene is expressed during human kidney embryogenesis. Kidney Int. 1995;47:1597-1603.
37. Simon MC. Gotta have GATA. Nat Genet. 1995;11:9-11.
38. Rivolta MN, Holley MC. GATA3 is downregulated during hair cell differentiation in the mouse cochlea. J Neurocytol. 1998;27:637-647.
39. Debacker C, Catala M, Labastie MC. Embryonic expression of the human GATA-3 gene. Mech Dev. 1999;85:183-187.
40. Orkin SH. GATA-binding transcription factors in hematopoietic cells. Blood. 1992;80:575-581.
41. Ordó n? ez NG. GATA3 is a highly sensitive and specific marker for parathyroid tumors. In press.
42. Liu H, Shi J, Wilkerson ML, et al. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: A useful immunomarker for breast and urothelial carcinomas. Am J Clin Pathol. 2012;138:57-64.
43. Higgins JP, Kaygusuz G, Wang L, et al. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol. 2007;31:673-680.
44. Raspollini MR, Sardi I, Giunti L, et al. Plasmacytoid urothelial carcinoma of the urinary bladder: Clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of a case series. Hum Pathol. 2011;42:1149-1158.
45. Antic T, Zhao L, Husain A, et al. Carcinomas with similar morphology and immunohistochemical profile: Does GATA3 make a difference [abstract]? Mod Pathol. 2013; 26(suppl 2):195A.
46. Gulmann C, Paner GP, Parakh RS, et al. Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract. Hum Pathol. 2013;44:164-172.
47. Zhao L, Paner GP, Taxy JB, et al. GATA3 expression in matched paired primary and metastatic urothelial carcinomas [abstract]. Mod Pathol. 2013;26(suppl 2):261A.
48. Moll R, Wu XR, Lin JH, et al. Uroplakins, specific membrane proteins of urothelial umbrella cells, as histological markers of metastatic transitional cell carcinomas. Am J Pathol. 1995;147:1383-1397.
49. Kaufmann O, Volmerig J, Dietel M. Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. Am J Clin Pathol. 2000;113:683-687.
50. Parker DC, Folpe AL, Bell J, et al. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. Am J Surg Pathol. 2003;27:1-10.
51. Huang HY, Shariat SF, Sun TT, et al. Persistent uroplakin expression in advanced urothelial carcinomas: Implications in urothelial tumor progression and clinical outcome. Hum Pathol. 2007;38:1703-1713.
52. Lotan TL, Ye H, Melamed J, et al. Immunohistochemical panel to identify the primary site of invasive micropapillary carcinoma. Am J Surg Pathol. 2009;33:1037-1041.
53. Chuang AY, DeMarzo AM, Veltri RW, et al. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol. 2007;31:1246-1255.
54. Ordó n? ez NG. Thrombomodulin expression in transitional cell carcinoma. Am J Clin Pathol. 1998;110:385-390.
55. Ordó n? ez NG. Transitional cell carcinomas of the ovary and bladder are immunophenotypically different. Histopathology. 2000;36:433-438.
56. Ordó n? ez NG, Mackay B. Brenner tumor of the ovary: A comparative immunohistochemical and ultrastructural study with transitional cell carcinoma of the bladder. Ultrastruct Pathol. 2000;24:157-167.
57. Wang HL, Lu DW, Yerian LM, et al. Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Am J Surg Pathol. 2001;25:1380-1387.
58. Mhawech P, Uchida T, Pelte MF. Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma. Hum Pathol. 2002;33:1136-1140.
59. Logani S, Oliva E, Amin MB, et al. Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: Histogenetic and diagnostic implications. Am J Surg Pathol. 2003;27:1434-1441.
60. Kaufmann O, Fietze E, Mengs J, et al. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol. 2001;116:823-830.
61. Munkberg J, McKenney J, Sharma S, et al. The diagnostic utility of S100P, PAX8, and P63 in the differential diagnosis of urothelial carcinoma of the renal pelvis and collecting duct carcinoma [abstract]. Mod Pathol. 2013;26(suppl 2):237A.
62. Villa C, Zhu B, Luan C, et al. GATA3 expression alteration in high grade and high stage urothelial carcinoma [abstract]. Mod Pathol. 2013;26(suppl 2):254A.
63. Warrick J, Palanisamy N, Siddiqui J, et al. GATA3 expression in nested, micropapillary, and plasmacytoid urothelial carcinomas [abstract]. Mod Pathol. 2013;26(suppl 2):256A.
64. Gonzalez-Roibon N, Chaux A, Sharma R, et al. The role of GATA3 in the differential diagnosis of upper tract urothelial and collecting duct carcinomas [abstract]. Mod Pathol. 2013;26(suppl 2):213A.
65. Esheba GE, Longacre TA, Atkins KA, et al. Expression of the urothelial differentiation markers GATA3 and placental S100 (S100P) in female genital tract transitional cell proliferations. Am J Surg Pathol. 2009;33:347-353.
66. Parikh P, Palazzo JP, Rose LJ, et al. GATA-3 expression as a predictor of hormone response in breast cancer. J Am Coll Surg. 2005;200:705-710.
67. Cakir A, Ekinci O, Isik Gonul I, et al. GATA3 expression and relationship between clinicopathological parameters in invasive breast carcinomas [abstract]. Mod Pathol. 2013;26(suppl 2):32A.
68. Deftereos G, Krishnamurti U, Silverman JF. GATA3 expression in different subtypes of invasive breast carcinoma and comparison with GCDFP15 and mammaglobin [abstract]. Mod Pathol. 2013;26(suppl 2):36A.
69. Surowiecka M, Blair C, Knapp D, et al. Significance of GATA3 expression in outcomes of breast cancer patients who received systemic chemo and/or hormonal therapy and clinicopathological features of GATA3 positive tumors [abstract]. Mod Pathol. 2013;26(suppl 2):71A.
70. Yang M, Nonaka D. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod Pathol. 2010;23:654-661.
71. Ellis CL, Chang AG, Cimino-Mathews A, et al. GATA3 is a useful marker for signet-ring adenocarcinoma of the urinary bladder [abstract]. Mod Pathol. 2013;26(suppl 2):208A.
72. Chopra S, Kim S, Bose S, et al. GATA-3 is helpful in differentiating primary mammary neuroendocrine carcinomas from metastatic neuroendocrine tumors [abstract]. Mod Pathol. 2013;26(suppl 2):33A.
73. Liu H, Shi J, Prichard J, et al. Immunohistochemical evaluation of GATA-3 expression in ER-negative breast carcinomas [abstract]. Mod Pathol. 2013;26(suppl 2):54A.
74. Deftereos G, Krishnamurti U, Silverman JF. GATA3 expression in cytology samples of metastatic breast versus gynecological carcinoma and comparison with GCDFP15 and mammaglobin [abstract]. Mod Pathol. 2013;26(suppl 2):87A.
75. Han J-H, Kang Y, Shin H-C, et al. Mammaglobin expression in lymph nodes is an important marker of metastatic breast carcinoma. Arch Pathol Lab Med. 2003;127:1330-1334.
76. Ciampa A, Fanger G, Khan A, et al. Mammaglobin and CRxA-01 in pleural effusion cytology: Potential utility of distinguishing metastatic breast carcinomas from other cytokeratin 7-positive/cytokeratin 20-negative carcinomas. Cancer. 2004;102:368-372.
77. Bhargava R, Beriwal S, Dabbs DJ. Mammaglobin vs. GCDFP-15: An immunohistologic validation survey for sensitivity and specificity. Am J Clin Pathol. 2007;127:103-113.
78. Fritzsche FR, Thomas A, Winzer KJ, et al. Co-expression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer. Histol Histopathol. 2007;22:1221-1230.
79. Sasaki E, Tsunoda N, Hatanaka Y, et al. Breast-specific expression of MGB1/mammaglobin: An examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers. Mod Pathol. 2007;20: 208-214.
80. Kanner WA, Galgano MT, Stoler MH, et al. Distinguishing breast carcinoma from Mu llerian serous carcinoma with mammaglobin and mesothelin. Int J Gynecol Pathol. 2008; 27:491-495.
81. Takeda Y, Tsuta K, Shibuki Y, et al. Analysis of expression patterns of breast cancer-specific markers (mammaglobin and gross cystic disease fluid protein 15) in lung and pleural tumors. Arch Pathol Lab Med. 2008;132:239-243.
82. Yan Z, Gidley J, Horton D, et al. Diagnostic utility of mammaglobin and GCDFP-15 in the identification of metastatic breast carcinoma in fluid specimens. Diagn Cytopathol. 2009;37:475-478.
83. Cohen C, Guarner J, DeRose PB. Mammary Paget?s disease and associated carcinoma. An immunohistochemical study. Arch Pathol Lab Med. 1993;117:291-294.
84. Brown RW, Campagna LB, Dunn JK, et al. Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site. Am J Clin Pathol. 1997;107:12-19.
85. Fiel MI, Cernaianu G, Burstein DE, et al. Value of GCDFP- 15 (BRST-2) as a specific immunocytochemical marker for breast carcinoma in cytologic specimens. Acta Cytol. 1996; 40:637-641.
86. Perry A, Parisi JE, Kurtin PJ. Metastatic adenocarcinoma to the brain: An immunohistochemical approach. Hum Pathol. 1997;28:938-943.
87. Wick MR, Ockner DM, Mills SE, et al. Homologous carcinomas of the breasts, skin, and salivary glands. A histologic and immunohistochemical comparison of ductal mammary carcinoma, ductal sweat gland carcinoma, and salivary duct carcinoma. Am J Clin Pathol. 1998;109: 75-84.
88. Honma N, Takubo K, Arai T, et al. Comparative study of monoclonal antibody B72.3 and gross cystic disease fluid protein-15 as markers of apocrine carcinoma of the breast. APMIS. 2006;114:712-719.
89. Moritani S, Ichihara S, Hasegawa M, et al. Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis? Hum Pathol. 2008;39:666-671.
90. Schwartz LE, Westra WH, Bishop JA. GATA3 immunoexpression in salivary gland neoplasms [abstract]. Mod Pathol. 2013;26(suppl 2):313A.
91. Soslow RA, Rouse RV, Hendrickson MR, et al. Transitional cell neoplasms of the ovary and urinary bladder: A comparative immunohistochemical analysis. Int J Gynecol Pathol. 1996;15:257-265.
92. Munari E, Gonzalez-Roibon N, Faraj SF, et al. GATA 3 immunohistochemical expression in primary and metastatic renal cell carcinomas [abstract]. Mod Pathol. 2013;26(suppl 2):236A-237A.
93. Steenbergen RD, OudeEngberink VE, Kramer D, et al. Down-regulation of GATA-3 expression during human papillomavirus-mediated immortalization and cervical carcinogenesis. Am J Pathol. 2002;160:1945-1951.
94. Atayar C, Poppema S, Blokzijl T, et al. Expression of the Tcell transcription factors, GATA-3 and T-bet, in the neoplastic cells of Hodgkin lymphomas. Am J Pathol. 2005;166:127-134.
95. Matsumoto Y, Horiike S, Ohshiro M, et al. Expression of master regulators of helper T-cell differentiation in peripheral T-cell lymphoma, not otherwise specified, by immunohistochemical analysis. Am J Clin Pathol. 2010;133:281-290.
96. So JS, Epstein JI. Gata3 expression in paragangliomas: A pitfall that could lead to misdiagnosis of urothelial carcinoma [abstract]. Mod Pathol. 2013;26(suppl 2):250A.
97. Savci-Heijink CD, Kosari F, Aubry MC, et al. The role of desmoglein-3 in the diagnosis of squamous cell carcinoma of the lung. Am J Pathol. 2009;174:1629-1637.
98. Ordónez NG. Value of PAX 8 immunostaining in tumor diagnosis: A review and update. Adv Anat Pathol. 2012;19:140-151.
99. Albadine R, Schultz L, Illei P, et al. PAX8 (+)/p63 (-) immunostaining pattern in renal collecting duct carcinoma (CDC): A useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract. Am J Surg Pathol. 2010;34:965-969.
100. Ozcan A, Shen SS, Hamilton C, et al. PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: A comprehensive immunohistochemical study. Mod Pathol. 2011;24:751-764.
101. Nigwekar P, Tamboli P, Amin MB, et al. Plasmacytoid urothelial carcinoma: Detailed analysis of morphology with clinicopathologic correlation in 17 cases. Am J Surg Pathol. 2009;33:417-424.
102. Ordónez NG. Value of thyroid transcription factor-1 immunostaining in tumor diagnosis: A review and update. Appl Immunohistochem Mol Morphol. 2012;20:429-444.
103. Ordó n? ez NG. Napsin A expression in lung and kidney neoplasia: A review and update. Adv Anat Pathol. 2012;19: 66-73.